Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 4/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.59 |
| ▸ | GAA | P10253 | 1/20 | 0.59 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | PPARG | P37231 | 1/20 | 0.57 |
| ▸ | NPC1 | O15118 | 2/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | CSF1R | P07333 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 2/20 | 0.55 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.55 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 2/20 | 0.55 |
| ▸ | NAMPT | P43490 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3778572 | 0.88 | PPARG (0.73) | LMNASMN1; SMN2ALDH1A1PPARGNPC1 | |
| SCHEMBL7605675 | 0.85 | HTT (0.72) | LMNASMN1; SMN2ALDH1A1TSHRPPARG | |
| SCHEMBL11625657 | 0.84 | USP2 (0.72) | CYP11B2LMNASMN1; SMN2ALDH1A1GAA | |
| SCHEMBL14322942 | 0.82 | ALDH1A1 (0.70) | CYP11B2LMNASMN1; SMN2ALDH1A1NAMPT | |
| SCHEMBL3771459 | 0.81 | ALDH1A1 (0.70) | LMNASMN1; SMN2ALDH1A1TSHRNPC1 | |
| SCHEMBL7608638 | 0.80 | KMT2A (0.58) | LMNASMN1; SMN2ALDH1A1TSHRCSF1R | |
| SCHEMBL1254144 | 0.79 | ALB (0.57) | LMNAALDH1A1GAAHTTMAPT | |
| SCHEMBL30572165 | 0.79 | ALB (0.57) | LMNAALDH1A1GAAHTTMAPT | |
| SCHEMBL11626565 | 0.79 | NPC1 (0.81) | LMNASMN1; SMN2ALDH1A1GAATSHR | |
| SCHEMBL8561634 | 0.79 | EPHX1 (0.60) | LMNASMN1; SMN2ALDH1A1GAATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100324086-A1 | COMPOUNDS AND METHODS | NOVASAID AB (SE) | 2010-12-23 | — | — | US | claimed |
| US-20100324086-A1 | COMPOUNDS AND METHODS | NOVASAID AB (SE) | 2010-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324086-A1 | COMPOUNDS AND METHODS | IL1B, LITAF, CYP11B1 | CYP11B2 4/4885LMNA 2648/4885SMN1; SMN2 1085/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.